NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT2031210422

Registered date:12/11/2021

Survey of proper use and occurrence of hyperkalemia after administration of MINNEBRO tablets in patients with hypertension - EBM Provider Cohort Study-

Basic Information

Recruitment status Recruiting
Health condition(s) or Problem(s) studiedhypertension
Date of first enrollment01/04/2008
Target sample size15000
Countries of recruitmentJapan
Study typeObservational
Intervention(s)

Outcome(s)

Primary OutcomeConduct serum potassium testing,, Development of hyperkalemia
Secondary Outcome

Key inclusion & exclusion criteria

Age minimumNot applicable
Age maximumNot applicable
GenderBoth
Include criteriaPrescription of MINNEBRO tablets has commenced during the enrollment period (May 13, 2019 to May 31, 2023). The diagnosis of hypertension exists on the same month as the date of the first prescription of this drug during the enrollment period. The date of the earliest medical record after the start date of the data period is 180 days or more prior to the date of the first prescription of this drug.
Exclude criterianone

Related Information

Contact

Public contact
Name Contact for GPSP
Address 3-5-1,Nihonbashi Honcho,Chuo-Ku,Tokyo Tokyo Japan 103-8426
Telephone +81-3-6225-1059
E-mail contact_gpsp@daiichisankyo.co.jp
Affiliation Daiichi Sankyo Co.,Ltd.
Scientific contact
Name Yomei Matsuoka
Address 3-5-1,Nihonbashi Honcho,Chuo-Ku,Tokyo Tokyo Japan 103-8426
Telephone +81-3-6225-1059
E-mail contact_gpsp@daiichisankyo.co.jp
Affiliation Daiichi Sankyo Co.,Ltd.